Macrocyclic-Antibiotic Hybrids: A Path to Clinical Candidates

Abdrrahman Shemsu Surur and Dianqing Sun*

Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai‘i at Hilo, Hilo, HI, United States

The tale of abate in antibiotics continued defense mechanisms that chaperone the rise of drug-defying superbugs — on the other hand, the astray in antibacterial drug discovery and development. Our salvation lies in circumventing the genesis of resistance. Considering the competitive advantages of antibacterial chemotherapeutic agents equipped with multiple warheads against resistance, the development of hybrids has rejuvenated. The adoption of antibiotic hybrid paradigm to macrocycles has advanced novel chemical entities to clinical trials. The multi-targeted TD-1792, for instance, retained potent antibacterial activities against multiple strains that are resistant to its constituent, vancomycin. Moreover, the antibiotic conjugation of rifamycins has provided hybrid clinical candidates with desirable efficacy and safety profiles. In 2020, the U.S. FDA has granted an orphan drug designation to TNP-2092, a conjugate of rifamycin and fluoroquinolone, for the treatment of prosthetic joint infections. DSTA4637S is a pioneer antibacterial agent under clinical development and represents a novel class of bacterial therapy, that is, antibody–antibiotic conjugates. DSTA4637S is effective against the notorious persistent S. aureus bacteremia, a revelation of the abracadabra potential of antibiotic hybrid approaches.

Keywords: antibiotic hybrid, macrocycle, macrocycle hybrid, TD-1792, TD-1607, TNP-2092, TNP-2198, DSTA4637S

INTRODUCTION

Relentlessness in developing resistance is imperiling the competence of the antibacterial arsenal. A global health crisis is heightened by the emergence and prevalence of multidrug-resistant bacteria pathogens, which are untreatable with commonly used antibiotics (Aslam et al., 2018). According to the landmark 2019 Centers for Disease Control and Prevention (CDC) estimate, there are over 2.8 million antibiotic-resistant infections every year in the United States, which account for a death every 15 min (CDC, 2019). The once though magic bullets are no longer producing magical chemotherapeutic effects. The rising and compounding antimicrobial resistances continue to mandate novel strategies in the antibacterial drug discovery and development process (Silver, 2011; Brown and Wright, 2016; Shang et al., 2020). The 2019 analysis of antibacterial agents in clinical development by the World Health Organization (WHO) indicates the current clinical pipeline is insufficient to alleviate the threats posed by antimicrobial resistance (WHO, 2019a).

ANTIBIOTIC COMBINATIONS VERSUS ANTIBIOTIC HYBRIDS

Single-target agents have dominated the current antibacterial collection, and bacteria seem capable of rendering all ineffective (East and Silver, 2013). Simultaneous use of drug molecules having different
molecular targets, or polypharmacology, was then considered more reliable to eliminate or at least slow the onset of resistance (Gray and Wenzel, 2020). Accordingly, concomitant use of antibiotics is often practiced by clinicians to prevent the development of resistance, broaden the spectrum of activity, and/or optimize the dose of drugs. In combination therapy, an adjuvant which may be inactive on its own is used with an antibiotic—a strategy called antibiotic-adjuvant approach (Liu et al., 2019). The adjuvant may enable entrance of the bona fide antibiotic by improving the membrane permeability, inhibit enzymes responsible for inactivation, or prevent the active efflux of the antibiotic (Liu et al., 2019; Tyers and Wright, 2019).

Antibiotic–antibiotic combination approach, on the other hand, entails the use of dynamic dual antibiotics to achieve drug synergism or suppress the development of resistance, hypothesizing that bacteria will not survive the one-two punch of the antibiotics (Tyers and Wright, 2019). This antibiotic cocktail approach has prolonged the clinical utilities of some antibiotics, albeit potential problems due to unfavorable pharmacokinetic (PK) interactions, and for several reasons, the boosted in vivo activity often does not translate well into in vivo efficacy in animal models or clinical settings (Klahn and Bronstrup, 2017; Domalaon et al., 2018). In a scenario where the combined drugs lack PK complementarities, such as dissimilar half-lives where a short-acting drug is excreted rapidly, or different tissue distributions where one component is barely distributed, the other component will become vulnerable from the aspect of development of resistance (Domalaon et al., 2018). For example, multiple resistance mechanisms have gradually limited the clinical use of co-trimoxazole involving the dihydrofolate reductase (DHFR) inhibitor trimethoprim and the dihydropteroate synthase (DHPS) inhibitor sulfamethoxazole, the esteemed example of the antibiotic combination approach (Eliopoulos and Huovinen, 2001). Pharmacokinetic disparities, such as dissimilar volume of distributions by the virtue of differences in hydrophobic properties between trimethoprim and sulfamethoxazole, might have contributed to the development of resistance (Brown, 2014). In addition, drug combination or co-formulation is also vulnerable to additive toxicities (Tamma et al., 2012). The need for taking multiple drugs, especially if different routes of administrations are involved, may also deface patients’ convenience (Fisher et al., 2020).

An attractive alternative to the mix and match antibiotic combinations is to bridge two pharmacophores by a metabolically stable covalent bond to generate a heteromeric synthetic construct, which behaves as a single chemical entity pertaining to PK parameters, a strategy otherwise known as an antibiotic hybrid (Pokrovskaya and Baasov, 2010; Klahn and Bronstrup, 2017). Diverse subjective definitions are forged for antibiotic hybrids. Generally, the antibiotic hybrid umbrella covers dual-acting antibiotic hybrids, divergent or multivalent antibiotics, antibiotic conjugates, chimeric antibiotics, and antibiotic hybrid prodrugs (Wang et al., 2016; Domalaon et al., 2018). The latter involves a cleavable linker between synthons, which can be metabolized only by a specific strain, a very useful strategy for the development of narrow-spectrum antibacterial agents (Domalaon et al., 2018; Jubeh et al., 2020). In the belligerence of drug resistance, molecules composed of two or more active structure motifs that are capable of acting at their respective targets have been extensively explored (Shavit et al., 2017). Selection of a matching partner in the antibiotic hybrid strategy is crucial so that the resulting dual-acting hybrid will unlikely suffer from cross-resistance. An organism may develop resistance to a dual-acting hybrid if it is not susceptible to the action of either drug (Parkes and Yule, 2016).

Over the past few decades, significant advances have been made in medicinal chemistry and chemical biology of macrocyclic compounds (Yu and Sun, 2013; Yudin, 2015). In contrast to large macromolecules and small synthetic molecules, macrocycles possess unique structural advantages and benefits from featuring both large molecules such as high potency and impeccable selectivity, and small molecules such as reasonable manufacturing costs, favorable PK, and the lack of immunogenicity (Peterson, 2017). The up-to-date comprehensive review of antibacterial agents in clinical pipeline (Butler and Paterson, 2020) along with reviews regarding the 14- to 15-membered macrolide hybrids (Janas and Przybylski, 2019) and their potential as anti-inflammatory agents (Paljetak et al., 2017) indicates the antibiotic hybrid approach is trending in the development of macrocyclic compounds. In this review, using terms such as “drugs” and “bacterial infections,” clinical trials listed in clinicaltrials.gov were searched meticulously. More than 2,000 clinical trials matched our search criteria, and the search results were cross-checked with the 2019 global observatory of the WHO for antibacterial products in clinical development (WHO, 2019b). Five novel macrocycle-based antibiotic hybrids under clinical developments, that is, TD-1792, TD-1607, TNP-2092, TNP-2198, and DSTA3647S, are highlighted and discussed.

HYBRIDS OF VANCOMYCIN

Although about 6 decades have passed since vancomycin (VAN, 1, Figure 1) was initially approved by the U.S. Food and Drug Administration (FDA) in 1958 and introduced into clinical practice, it is still commonly used for the treatment of many Gram-positive bacterial infections and often the last resort in modern treatment of drug-resistant infections (Okano et al., 2017). However, a dark cloud lids over the use of 1, as evidenced by widespread VAN-resistant Enterococci (VRE) and VAN-resistant Staphylococcus aureus (VRSA) and the loss of clinical efficacy against severe methicillin-resistant S. aureus (MRSA) infections (Faron et al., 2016). Vancomycin has continued to be captured in the spotlight in antibacterial drug development; its unique clinical successes, absence of cross-resistance with other antibacterial classes, a significant time span (30 years) between discovery and appearance of the first resistant strains in VRE, and advances in structural determinations.
The lipid intermediate II (a membrane-anchored cell wall precursor) and transpeptidase (the penicillin-binding protein), the cellular targets of 1 and cephalosporins, respectively, are in close proximity and catalyze sequential roles in the bacterial cell wall biosynthesis. Consequently, their hybrid molecule might be able to inhibit both targets simultaneously and therefore have superior bactericidal properties (Long et al., 2008a). As mentioned above, 1 is equipped with at least three potential attachment sites (V_C, V_R, and V_D) (Long et al., 2008a; Blaskovich et al., 2018). Similarly, the C-3 pyridinium (C_P) moiety, the Z-oriented oxime (C_O), and thiazolylamino (C_N) groups of the C-7 side chain of 2 are suitable attachment sites in a cephalosporin nucleus (Figure 1, Long et al., 2008a). All possible nine hybrid heteromers between the above-mentioned attachment sites were synthesized via an amide linker and exhibited excellent activity against a select panel of Gram-positive bacteria pathogens, including MRSA and vancomycin intermediate-resistant S. aureus (VISA) (Long et al., 2008a). Cefilavancin was among the two most promising heteromers, with an MIC90 value of 0.03 μg/ml against MRSA isolates (Long et al., 2008a; Blais et al., 2012). Furthermore, in vitro studies revealed that THRX-169797 (2), the cephalosporin constituent of 3, was much less active than 3 against all S. aureus isolates tested (Blais et al., 2012). The murine neutropenic thigh infection model of MRSA was extended to 3. The ED50 of 0.19 mg/kg for 3 was 40 times more effective than the ED50 of that for 1, with an ED50 of 8.1 mg/kg in their assay (Long et al., 2008a). Consequently, 3 was selected and advanced as a clinical candidate for further development.

Cefilavancin also showed very potent activity against the heterogeneous VISA (hVISA), with minimum inhibitory concentration (MIC90) values of 0.03 μg/ml against 39 isolated strains of hVISA, relative to 2 μg/ml for 1 (Blais et al., 2012). In addition, 3 was the most active (MIC90 = 0.125 μg/ml) against various clinical isolates of VAN-intermediate staphylococcal species (VISS), heterogeneous VISS (hVISS), and VRSA, compared to daptomycin, quinupristin-dalfopristin, and linezolid (Leuthner et al., 2010). A similar study identified the effect of plasma proteins on the potency of 3 as low, and the MIC90 value remained the lowest compared to all comparators (Leuthner et al., 2010). Moreover, the positive results from clinical trials have supported the continued development of 3. In phase 1 studies, plasma concentrations after intravenous (IV) administration of 2 mg/kg body weight were continuously above the MIC value at which 100% MRSA isolates were inhibited (Blais et al., 2012). In phase 2 studies, the efficacy of 3 was compared with that of 1 in the treatment of cSSSIs. The cure rate at the end of the treatments with 1 and 3 was 90.7% and 91.7%, respectively (Stryjewski et al., 2012). The incidence of the most common adverse effects was similar in both groups, except for itching, which was more common in volunteers in the VAN arm (WHO, 2019a; Adis Insight, 2020). Currently, Theravance Biopharma and R-Pharm are conducting a phase 3 clinical development of 3 in Russia (WHO, 2019a; Adis Insight, 2020).

The hybridization of the nuclei in 3, but with a longer amide linker and different attachment positions, led to TD-1607 (4) (Figure 2, Fatheere et al., 2005). In 4, the aryl group closest to the C-terminus of 1 (V_R) is aminomethylated and linked to the pyridinyl substituent (C_P) from the bicyclic lactam of cephalosporin
However, Theravance BioPharma has discontinued further clinical phase 1 studies on the safety, tolerability, and PK of et al., 2014; Liapikou et al., 2017). Single and multiple ascending dose comparisons, including 0.06 μg/ml against 1,026 MRSA isolates procured worldwide (Sader et al., 2014) and 12–14 fluoroquinolones as the best concomitant drugs against rifampin (Wells et al., 2018). However, the in vitro antagonism observed between rifampin and the fluoroquinolone class (Murillo et al., 2008) and the need to take rifampin orally and fluoroquinolones intravenously during the initial phase of the treatment regimen are major limitations for clinical use of this combination (Ma and Lynch, 2016). Rifampin inhibits bacterial RNA synthesis which may weaken the bactericidal effect of fluoroquinolones by impeding the supercoiling of DNA (Zimmerli and Sendi, 2019). To address these, a resolution by introducing a covalently linked hybrid of rifampin and a fluoroquinolone pharmacophore was proposed. Furthermore, fluoroquinolones

**FIGURE 2 |** Chemical structures of VAN hybrids, ceftavancin (3, TD-1792), and TD-1607 (4).

(Fatheree et al., 2005; Blaskovich et al., 2018). TD-1607 exerts its antibacterial activity by inhibiting cell wall biosynthesis; in vitro microbiological profiling showed a rapid and potent bactericidal effect against Gram-positive organisms (Sader et al., 2014). Compound 4 proved to be the most effective against all comparators, including 1, with MIC values between 0.008 and 0.06 μg/ml against 1,026 MRSA isolates procured worldwide (Sader et al., 2014; Liapikou et al., 2017). Single and multiple ascending dose phase 1 studies on the safety, tolerability, and PK of 4 were conducted in healthy volunteers (NCT01791049, 2013; NCT01949103, 2013). However, Theravance BioPharma has discontinued further clinical developments of 4 (Butler and Paterson, 2020).

**Synthesis of Vancomycin Hybrids**

Chemical syntheses of VAN conjugates 3 and 4 involved a series of steps to construct the cephalosporin synthon attached to a linker and an eventual coupling with vancomycin (Scheme 1). The synthesis of a cephalosporin and an amide anchor motif in 3 started by coupling N-Boc–protected bromopropylamine 5 with the hydroxylimino moiety of a trityl-protected aminothiazolyl residue 6 (Long et al., 2008a). Following ester hydrolysis of 7 and subsequent chlorination of the thiazolyl ring in 7 or 8 using N-chlorosuccinimide (NCS) yielded 9 or 10, respectively. Intermediates 9 and 10 were next coupled with 7-amino-3-chloromethyl-3-cephem-4-carboxylic acid p-methoxybenzyl ester hydrochloride salt (ACLE). The 3-chloro good leaving group in the ACLE moiety was replaced with pyridine or 4-(N-tert-butoxycarbonyl)aminomethyl pyridine to give 11 or 12, respectively (Fatheree et al., 2005; Long et al., 2008a). The key cephalosporin intermediates 13 and 14 were synthesized by global deprotection of their corresponding precursors in TFA. Finally, VAN 1 was attached directly to 13 through amide bond formation to afford target compound 3 (Fatheree et al., 2005; Long et al., 2008a). Unlike the direct coupling in 3, target compound 4 was synthesized via sequential bifunctional amide coupling of the cephalosporin Cα synthon 14 and the VAN V_R synthon via the di-HOAt ester of adipic acid (Fatheree et al., 2005; Long et al., 2008a).

**HYBRIDS OF RIFAMYCINS**

Various clinical guidelines for the treatment of staphylococcal prosthetic joint infection (PJI), including the Infectious Diseases Society of America (IDSA) guideline, recommend rifampin with a fluoroquinolone companion (Osmon et al., 2013; Berbari et al., 2020). First, rifamycins are the drug of choice for persistent bacterial infections such as PJI (Robertson et al., 2008). Rifampin intervenes critical gene transcription process and prevents spread to deep-seated infection sites, crafting a clinical success against slow-growing and nonreplicating metabolic stages of bacteria (Robertson et al., 2008; Ma and Lynch, 2016). Second, the formation of bacterial biofilms, a polysaccharide glycocalyx that provides a mechanical shield from antibiotics and immune system of the host, over the prosthesis is a central mechanism in the pathogenesis of PJI (Taha et al., 2018). According to various in vitro and/or in vivo animal model studies, rifampin diffuses well into biofilm and produces effective killing against biofilm-associated bacteria (Sanchez et al., 2015). Third, a point mutation in the rpoB gene that encodes the β-subunit of RNA polymerase confers a high resistance to rifampin (Aubry-Damon et al., 1998; Silver, 2011), and a companion drug may be needed to slow down the development of resistance. In this context, in vivo and clinical data indicated fluoroquinolones as the best concomitant drugs with rifampin (Wells et al., 2018). However, the in vitro antagonism observed between rifampin and the fluoroquinolone class (Murillo et al., 2008) and the need to take rifampin orally and fluoroquinolones intravenously during the initial phase of the treatment regimen are major limitations for clinical use of this combination (Ma and Lynch, 2016). Rifampin inhibits bacterial RNA synthesis which may weaken the bactericidal effect of fluoroquinolones by impeding the supercoiling of DNA (Zimmerli and Sendi, 2019). To address these, a resolution by introducing a covalently linked hybrid of rifampin and a fluoroquinolone pharmacophore was proposed. Furthermore, fluoroquinolones
are one of the most widely used classes in the antibiotic hybrid paradigm (Pham et al., 2019). A dual mechanism against topoisomerase IV and DNA gyrase, which may compensate for any interference shadowed by steric hindrance from a linker (Pokrovskaya and Baasov, 2010) or a second component with suitable attachment sites for bulky partners and stability under different synthetic conditions, are the arguments put forward for the fluoroquinolones (Fedorowicz and Sańczewski, 2018).

As previously reported (Ma and Lynch, 2016), open spaces and hence convenient positions for attachments to the C-3 and C-25 positions of rifampin were identified from a co-crystallized structure of rifampin and RNA polymerase. This is further illustrated in Figure 3 using a recently reported co-crystal structure (Molodtsov et al., 2017). Structure–activity relationships (SARs) from a series of spirorifamycins disclosed that a heterocycle fusing with both C-3 and adjacent C-4 of rifamycin can serve as an attachment site for the second partner (Kim et al., 2007). The carbonyl group at C-11 can be used as a conjugation site. Functionalization of the C-11 carbonyl to oxime led to a series of novel 11-deoxy-11-hydroxyiminorifamycin derivatives, with better or equivalent activity against the RNA polymerase of S. aureus (Li et al., 2007). Similarly, the C-25 position can be used for attachment of a companion after replacement of the acetyl group with a carbamate. A series of C-25 carbamate rifamycins showed improved antimycobacterial activity and absence of inactivation through ribosylation of C-23 alcohol by ADP-ribosyl transferase of Mycobacterium smegmatis (Combrink et al., 2007). Various matching partners of rifamycins have been explored, with rifamycin–quinolones being the most studied (Ma and Lynch, 2016). SARs from approximately 300 rifamycin–quinolone hybrids revealed that the linker significantly influenced biological activity (Robertson et al., 2008; Klahn and Bronstrup, 2017). Partnering a rifamycin nucleus with a quinazolinone, a bioisostere of quinolone, provided the activity-leading conjugate, called CBR-2092 or TNP-2092 (15) (Figure 4, Ma and Lynch, 2016). Furthermore, the
antibacterial pipeline. 1) In several facets, a credence to hybrid pharmaceuticals in the retains activity against resistance mediated by mutations of the ef-a substrate for ef-

Robertson et al., 2008; Ma and Lynch, 2016). 2) TNP-2092 is not against RNA polymerase, DNA gyrase, and topoisomerase IV elements of treatment failure in PJI, (coNS), the main causative agents and major Staphylococci respective binding sites (Ma and Lynch, 2016). The optimal linker in by a linker that resembles a covalently bound side chain of rifampin rifamycin and the C-8 of quinazolinone pharmacophores are bound

against bacterial isolates that are resistant to cipro

quinazolinone core possesses activity against the ParCS80F variant of topoisomerase IV, the activity that is not retained by ciprofloxacin. This provides an explanation for the activity of 15 against bacterial isolates that are resistant to ciprofloxacin alone or in combination with rifampin (Fisher et al., 2020). In 15, the C-3 of rifamycin and the C-8 of quinazolinone pharmacophores are bound by a linker that resembles a covalently bound side chain of rifampin and ABT-719 (Ma and Lynch, 2016). The optimal linker in 15 also clamps the binding of rifamycin and quinazolinone motifs to their respective binding sites (Ma and Lynch, 2016). TNP-2092 was superior to rifampin plus ciprofloxacin in several facets, a credence to hybrid pharmaceuticals in the antibacterial pipeline. 1) In S. aureus and coagulase-negative Staphylococci (coNS), the main causative agents and major elements of treatment failure in PJI, 15 has multi-targeted activities against RNA polymerase, DNA gyrase, and topoisomerase IV (Robertson et al., 2008; Ma and Lynch, 2016). 2) TNP-2092 is not a substrate for efflux pumps such as NorA or MepA and therefore retains activity against resistance mediated by mutations of the efflux system. In addition, the lack of efflux effectively traps 15 within bacteria (Ma and Lynch, 2016). Almost half of fluoroquinolone-resistant strains have enhanced expression of norA or mepA gene (Robertson et al., 2008). 3) TNP-2092 appears to overcome the antagonism between rifampin and ciprofloxacin (Murillo et al., 2008); in a minimum biofilm bactericidal concentration (MBBC) evaluation, ciprofloxacin plus rifampin exhibited MBBC levels higher than the MBBC values of ciprofloxacin alone in 11 of 40 S. aureus and in zero of 40 S. epidermidis isolates (Fisher et al., 2020). 4) TNP-2092 showed strong activity against pathogens resistant to its constituents. The difference in MIC values of 15 between the wild-type (CB190) and rifamycin-resistant S. aureus (CB370, rpoB^{I527Y}) was smaller, unlike 31,250 folds for rifampin. Compound 15 exhibited no activity difference between CB190 and fluoroquinolone-resistant S. aureus (CB814, gyrA^{384I}, ParC^{S80F}), while nearly 67-fold difference was observed for ciprofloxacin (Robertson et al., 2008). Against rifampin-resistant S. epidermidis strains, IDRL-10005 (rpoB^{347IE} rpoC^{I527Y}) and IDRL-10692 (rpoC^{S80F}), on the other hand, 15 had MIC values of 0.06 and 0.125 μg/ml, respectively; in contrast, rifampin had high MIC values of ≥4 μg/ml, and ciprofloxacin had MIC values of 8 and 1 μg/ml, respectively (Fisher et al., 2020). 5) Safety concerns related to constituent elements such as hERG inhibition and induction of CYP3A4 isoenzyme were not observed in 15 (Ma and Lynch, 2016).

Rifaximin, a member of the rifamycin family and a nonsystemic antibiotic, has been approved for the treatments of travelers’ diarrhea, hepatic encephalopathy, and irritable bowel syndrome without constipation (Lexicomp, 2021). Its clinical benefits were thought to be mediated through altered gastrointestinal (GI) microbiota or dysbiosis (Chey et al., 2020). Antibacterial evaluations of 15 against a representative panel of GI bacteria revealed similarities with rifaximin (Yuan et al., 2020). Interestingly, 15 was more active against Gram-negative bacteria such as E. coli and A. baumannii, which were resistant to rifampin (Ma and Lynch, 2016). The low oral bioavailability of 15, 1.81% in rats and 0.315% in dogs, can offer additional benefits for local treatment of intestinal diseases (Yuan et al., 2020). The main strategy for the treatment of hepatic encephalopathy, which is closely related to hyperammonemia, is to regulate urease-producing bacteria located in the gut (Liu et al., 2018). Against a panel of urease-producing strains, 15 was more active than rifampin against Gram-negative bacteria such as Helicobacter pylori (H. pylori) and Salmonella strains but lower activity against beneficial commensals such as B. infantis and B. bifidum (Yuan et al., 2020). TNP-2092 appears to be an attractive candidate for the treatment of the urease-producing C. difficile. Compared to the standard treatments of C. difficile infections (CDIs), vancomycin and metronidazole, 15 showed superior activity against various isolates of C. difficile (Yuan et al., 2020). In addition, following 7 days’ treatment with 15, the changes in the percentage of intestinal microbiota were temporary and generally returned to pretreatment levels. This explains the nonrecurrence of CDIs after treatment with 15 (Yuan et al., 2020). The standard treatments interfere with the intestinal microbiota and are the leading factors for the recurrence of CDIs (Tsutsumi et al., 2014).

The phase 1 study of 15 on tissue distribution, PK, safety, and tolerability in participants undergoing primary total hip replacement or knee arthroplasty is being planned, but
participants have not been recruited yet (NCT04294862, 2021). Nonetheless, the phase 2 study of 15 for the treatment of ABSSISs was completed in September 2020 (NCT03964493, 2019). TenNor Therapeutics presented “topline” phase 2 results of 15 for the treatment of ABSSISs at the 2020 China Biomed Innovation and Investment Conference (CBIIC) (TenNor, 2020b). In 2020, the FDA has granted an orphan drug status for the IV use of 15 for the treatment of PJI (PR Newswire, 2020).

**Synthesis of TNP-2092**

A scheme suitable for kilogram quantity synthesis of 15 was reported (Ma and Lynch, 2016). The scheme involved an initial five-step synthesis of the linker intermediate 18, which was subsequently coupled with the fluoroquinolone core 19 under reflux in acetonitrile, to give 20. The fluoroquinolone-linker motif 20 was further processed via hydrolysis of ethyl ester and Boc deprotection to afford 21 using LiOH and TFA, respectively. Eventually, following the conversion of the piperidine moiety in 21 to a hydrazine, 15 was produced by coupling the hydrazine variant of 21 with 3-formyl rifamycin (Ma and Lynch, 2016; Scheme 2).

Besides 15, TenNor Therapeutics is also developing a conjugate of rifamycin and metronidazole (Figure 5), also known as TNP-2198 (22). Metronidazole is used to treat infections caused by anaerobic bacteria and is the first-line treatment for bacterial vaginosis (BV) (Jones, 2019). However, the effectiveness of metronidazole against Gardnerella vaginalis (GV), the leading cause of BV, is associated with 58% recurrence (Bradshaw et al., 2012). The underlying factor for treatment failure is resistance by biofilms that form a protective shield to reduce the penetration of metronidazole (Ma et al., 2020). Leaving the essential nitroimidazole moiety intact, conjugates of metronidazole (Patel et al., 2021), via N2-alkyl or 2-methyl linker or both, with different structural nuclei such as thiomorpholine-1,1-dioxide, have resulted in hybrids with superior activity against metronidazole sensitive as well as resistant H. pylori strains (Rossi and Ciofalo, 2020). Accordingly, the pharmacophore of metronidazole, a 5-nitroimidazole motif, was conjugated with rifamycin, an established agent against biofilm-forming pathogens. The resulting 22 showed strong synergistic property against GV (Ma et al., 2020). The MIC value of 0.004 μg/ml of 22 against GV was significantly lower than those of its constituents, with MICs of 4 and 0.5 μg/ml for metronidazole and rifampicin, respectively (Ma et al., 2020). In addition, the spectrum activity of 22 was not limited to GV but also active against other pathogens that can cause BV and other anaerobic bacteria. Apart from a few BV-causing bacteria where equivalent activity was displayed, the MIC values of 22 were 100 to 1,000 folds lower than those of metronidazole (Ma et al., 2020). Very recently, TenNor Therapeutics initiated a phase 1b/2a clinical development of 22 for the treatment of H. pylori infection (TenNor, 2020a). Additional clinical development status of 22 is listed in Table 1.
| Macrocycle hybrid | Molecular weight (Dalton) | miLogP | tPSA | Select MIC<sub>90</sub> (µg/ml) | Microorganism | In vivo ED<sub>50</sub> (mg/kg) | Half-life (h) | Company | RoA | Clinical development status |
|-------------------|---------------------------|--------|------|-----------------------|---------------|-----------------------------|-------------|---------|----|--------------------------------|
| TD-1792<sup>a</sup> | 1,984.28                  | −4.68  | 673.39 | 0.03                  | MRSA, hVISA   | 0.19                        | 1.7         | Theravance biopharma/R-pharm | IV    | Phase 2 completed in 2007 NCT00442832, (2006); phase 3 registered in Russia WHO (2019a) |
| TD-1607<sup>b</sup> | 2,170.49                  | −4.98  | 751.81 | 0.008−0.06           | MRSA          | 0.11                        | N/A         | Theravance biopharma/R-pharm | IV    | Phase 1 completed in 2014 NCT01949103, (2013); phase 1b completed in 2013 NCT01791049, (2013) |
| TNP-2092<sup>c</sup> | 1,205.39                  | 5.85   | 282.18 | 0.015                 | MSSA, MRSA    | 1.4−3.8                     | 0.4−4.1     | TenNor therapeutics         | IV    | Phase 1 for PJI (not yet recruiting) NCT04294862, (2021); phase 2 for ABSSSIs completed NCT03964493, (2019) |
| TNP-2198<sup>d</sup> | 944.05                    | 2.70   | 269.21 | 0.004                 | GV            | N/A                         | N/A         | TenNor therapeutics         | PO    | Phase 2 ongoing in China Preclinical development |
| DSTA4637S<sup>e</sup> | 149 kDa (DM-4637A TAb); 927.06 (dmDNA31) | 4.30 (dmDNA31) | 230.67 (dmDNA31) | 0.004 µM (dmDNA31) | MRSA (USA300) | N/A                         | 16.5−21.5 days | Genentech, Inc./Roche | IV    | Phase 1 completed in 2016 NCT02596399, (2015); phase 1b completed in 2020 NCT03162250, (2017) |

MiLogP: the logP prediction developed at Molinspiration. tPSA: topological polar surface area. Both miLogP and tPSA values were calculated using Molinspiration cheminformatics (https://www.molinspiration.com/). RoA: route of administration; N/A: not available.

<sup>a</sup>MIC value (Blais et al., 2012); in vivo ED<sub>50</sub> value (Long et al., 2008a); terminal half-life in mice (Hegde et al., 2012).

<sup>b</sup>MIC value (Sader et al., 2014); in vivo ED<sub>50</sub> value (Long et al., 2008a).

<sup>c</sup>MIC value, in vivo ED<sub>50</sub> and plasma half-life (Ma and Lynch, 2016); IV for medical device associated bacterial biofilm infections, PO for hepatic encephalopathy and inatable bowel symptom diarrhea, topical for superbugs and diabetic foot infection (TenNor Therapeutics, 2021).

<sup>d</sup>MIC value (Ma et al., 2020); PO for H. pylori and other anaerobic bacterial infections (TenNor Therapeutics, 2021).

<sup>e</sup>MIC value (Ma et al., 2020); PO for H. pylori and other anaerobic bacterial infections (TenNor Therapeutics, 2021).

<sup>f</sup>MIC value (Lehar et al., 2015); mean half-life of DSTA4637S TAb from phase 1 clinical trial (Peck et al., 2019).
Antibody–antibiotic conjugation (AAC), in addition to the antibiotic-antibiotic hybrids mentioned above, is practiced for the conjugation of rifamycins. The antibody–drug conjugate (ADC) is mainly used in cancer immunotherapy, to selectively deliver a cytotoxic warhead using a labeling antibody bound via a linker (Beck et al., 2017). In 2015, the extension of ADC to the treatment of bacterial infections caused by *S. aureus* was first coined by Lehar et al. (2015). The infamous *S. aureus* is able to survive the wrath of antibiotics by internalizing into phagocytes (Fraunholz and Sinha, 2012). This intracellular reservoir has enabled long-term colonization of a host and promoted development of resistance, which explains the recurrences associated with invasive *S. aureus* infections (Lehar et al., 2015; Peyrusson et al., 2020). Despite available appropriate treatments, *S. aureus* remains a leading cause of death related to bacterial infections, with mortality rates of around 20–30% (Yilmaz et al., 2016). A new strategy capable of effectively eliminating the responsible intracellular foci of *S. aureus* was needed. As such, a novel AAC platform, THIOMAB™ antibody–antibiotic conjugate (TAC), was utilized to target the intracellular *S. aureus*. DSTA4637S (23) (Figure 6) is a novel conjugate of an antibiotic with an anti-*S. aureus* antibody, which represents the first AAC in this class under clinical development (Lehar et al., 2015; Mariathasan and Tan, 2017; Poreba, 2020). Mechanistically, the large-sized 23 cannot diffuse into mammalian cells. In systemic circulation and tissues, the antibody directs the binding of the conjugate to *S. aureus*, enabling the uptake of appended bacteria into phagocytes via opsonization (Cai et al., 2020). The linker is cleaved by cathepsins inside the phagolysosome to release the active antibiotic that can eliminate the conjugate bound and other existing bacteria (Lehar et al., 2015; Cai et al., 2020).

In DSTA4637S, an artificially engineered monoclonal antibody MSTA3852A against *S. aureus* from human immunoglobulin (IgG1) and 4-dimethylaminopiperidino-hydroxybenzoaxazino rifamycin, dmDNA31 (rifalogue), are linked by a protease cleavable valine-citrulline (vc) linker (Lehar et al., 2015; Poreba, 2020). MSTA3852A was selected from >40 anti-*S. aureus* antibodies that originated from the blood of patients recovering from different *S. aureus* infections. The highest level of binding by those antibodies was directed against a major component in the cell wall of *S. aureus*, the wall-teichoic acids (WTAs) (Lehar et al., 2015; Deng et al., 2019).

In the majority of *S. aureus* lineages, WTA is composed of up to 40 repeating units of ribitol phosphate (RboP) that are...
covalently linked to the N-acetylmuramic acid (MurNAc) residue of the peptidoglycan layer by a short polysaccharide anchor unit (Figure 7, Weidemaier and Peschel, 2008; Fong et al., 2018). The anchor unit is composed of glycerol-phosphate (GroP) units (1–3x), N-acetyl-d-mannosamine (ManNAc), and N-acetyl-d-glucosamine-1-phosphate (GlcNAc-1-P) (Winstel et al., 2014). RboP can be modified with α- or β-O-linked N-acetyl-d-glucosamine (α/β-O-GlcNAc) residues and d-alanine. Those modifications were reported to be essential for developing resistance to methicillin and cationic antimicrobial peptides (Brown et al., 2012). In MRSA strains, modifications with β-1,4-GlcNAc and α-1,3-GlcNAc are catalyzed by glycotransferases TarS and TarM, respectively (Brown et al., 2012; van Dalen et al., 2019). Recently, Gerlach et al. have identified an alternative glycotransferase for MRSA, TarP, which catalyzes the glycosylation of β-1,3-GlcNAc on WTA (Gerlach et al., 2018). This alternative glycans modification was poorly immunogenic and sabotaged the recognition by host antibodies (Gerlach et al., 2018). WTA's are promising antigens being pursued for the development of novel vaccines against MRSA (van Dalen et al., 2019).

The majority of the host anti-β-S. aureus antibodies target β-1,4-GlcNAc, followed by β-1,3-GlcNAc, and few antibodies are reactive to α-1,4-GlcNAc, albeit the underlying reason is not fully understood (van Dalen et al., 2020). The binding pattern between antibodies and β-WTA was then characterized by co-crystallizing the Fab fragment of anti-β-WTA antibodies with a minimal synthetic repeat of β-WTA, a β-glycosidic bonded unit between ribitol-1-phosphate (Rbo-1-P) or ribitol-5-phosphate (Rbo-5-P) and GlcNAc (Lehar et al., 2015; Fong et al., 2018). Antibodies displayed a preserved mechanism to specifically recognize the β-anomer mimic, albeit different residues were involved in different antibodies (Fong et al., 2018). In the co-crystal structures of antibody 4462 or 6078, for example, the pyranose ring of GlcNAc of the mimic was stacked against the amide chain of N95 or the indole side chain of W50, respectively (Figure 8, Fong et al., 2018). In antibody 4462, the C-5 phosphate of the WTA mimic formed ionic interactions with K94 (Figure 8A). Similarly, the interaction between the 5-phosphate and Y94 in antibody 6078 was indicated for selectivity to β-linked GlcNAc (Figure 8B, Fong et al., 2018).

Lehar et al., using a co-crystal structure of antibody 4497 with 1-phosphoribitol β-WTA, also revealed an arginine “tweezers” motif by Arg27d and 28 that dictated the β-anomer-specific recognition via triangulation of the ribitol phosphodiester backbone in relation to the GlcNAc moiety (Figure 8C, Lehar et al., 2015).

Various features of rifalogue (dmDNA31) were considered in the selection of the payload for anti-β-S. aureus antibody 4497. dmDNA31 had an MIC value of $4 \times 10^{-9}$ M against MRSA (USA300), with effective killing property against these well-recognized persister cells (Lehar et al., 2015). Persister cells are dormant, nonreplicating bacteria with a high level of tolerance to antibiotics. Nondividing MRSA isolates inside macrophages were effectively eliminated by dmDNA31 (Lehar et al., 2015). Moreover, dmDNA31 conjugate was inactive against extracellular bacteria, indicating the safety of the conjugate (Shopsin et al., 2016).

V112C mutagenesis of the antibody MSTA3852A, in which a valine in the light chain IgG1 is precisely replaced by a reactive cysteine residue, enables site-specific conjugation with a drug–antibody ratio (DAR) of two vc-dmDNA31 per antibody (Deng et al., 2019). Site-specific conjugation in ADC enables a direct and homogeneous conjugation of a drug (Zhou, 2017). Stochastic or random conjugation, on the other hand, often leads to heterogeneous products, with each subtype having different PK properties, efficacy, and safety profiles. In stochastic conjugates, there are also concerns about higher DAR, which are relatively more active in vitro, less tolerated, and exhibit rapid elimination than conjugates with lower DAR (Gauzy-Lazo et al., 2020). THIOMAB™ is one such site-specific conjugation technology that led to 23 (Lehar et al., 2015; Wang-Lin and Balthasar, 2018; Gauzy-Lazo et al., 2020). The linker in 23 will be cleaved within minutes following the entry of the opsonized S. aureus, and when tested inside human macrophages, epithelial and endothelial cells, AAC-opsonized MRSA isolates were killed in all cases (Lehar et al., 2015). In an intravenous mice infection model, the efficacy of 23 was superior than that of 1. The efficacy of 1 declined when administered after 7–24 h of infections, suggesting the failure of 1 due to the internalization of MRSA into host cells (Lehar et al., 2015). After 24 h of infection, a single dose of TAC was effective and superior to the twice-daily dose of 1 (Lehar et al., 2015).
The preclinical PK properties of TAC 23 were profiled in mice, rats, and cynomolgus monkey (Zhou et al., 2016; Deng et al., 2019). The PK profiling of TAC involved the analysis of three analytes: TAC total antibody (TAb) which includes fully conjugated (DAR 2), partially conjugated (DAR 1), and unconjugated antibodies (Zhou et al., 2016). The PK properties of typical monoclonal antibody-based therapeutics, that is, short distribution, slow clearance, and long half-life, were demonstrated by DSTA4637A (the preclinical liquid formulation of 23) in various in vivo animal studies (Zhou et al., 2016; Deng et al., 2019). In mice, the conjugation extended the half-life (~3–4 h) of unconjugated dmDNA31 to 4 days in ac-dmDNA31. A similar clearance between 23 and the unconjugated antibody in mice indicated the conjugation of dmDNA31 had relatively little effect on the clearance of the TAb (Zhou et al., 2016). Comparable PK properties of DSTA4637A TAb and MSTA3852A were also found in rats and monkey (Deng et al., 2019). Three main reasons can explain the similar PK profiles between DSTA4637A and MSTA3852A. First, conjugates with a DAR of 2–4 generally have slower clearance rates and longer half-lives than conjugates with a higher DAR (Deng et al., 2019). Second, THIOMAB™ technology allows uniform conjugation on the engineered cysteine without disrupting the inter-disulfide bonds in the antibody (Sussman et al., 2018), and therefore minimal PK changes after conjugation. Third, drug loading and hydrophobicity factors are causes that result in significant changes in PK properties (Kamath and Iyer, 2016). The hydrophilic property of dmDNA31 is expected to slow down clearance and extend the half-life of 23 (Deng et al., 2019). A minimal physiologically based PK model in mice indicated a low level of drug interactions between DSTA4637A and cytochrome P450 substrates. This model of PK disposition also indicated the liver and spleen, where phagocytes are usually accumulated, may contain high concentrations of dmDNA31 (Wang-Lin et al., 2018).

Preclinical safety evaluations with high doses of 23, up to 250 and 500 mg/kg in monkeys and rats, respectively, were well tolerated (Deng et al., 2019). In 2019, the results of the phase I investigations on the safety, PK, and immunogenicity in healthy volunteers were published, which showcased the favorable profiles of 23 for human use (NCT02596399, 2015; Peck et al., 2019). No serious adverse effects were observed in the dose range between 5 and 150 mg/kg; no clinically significant changes in laboratory or vital signs or antibody responses induced by 23 were observed (Peck et al., 2019). Therefore, further clinical development of 23 for S. aureus infections is expected following these favorable safety and PK profiles in human volunteers (Peck et al., 2019).

LIMITATIONS AND WAYS FORWARD IN MACROCYCLE-ANTIBIOTIC HYBRID APPROACH

The increase in molecular weight is a major limitation of the antibiotic hybrid approach. The resulting low oral bioavailability of such conjugates may impede oral dosage formulations for systemic applications (Gupta and Datta, 2019). However, this opens the door to selectivity and efficacy for local treatments of gut and liver diseases (Ma and Lynch, 2016). In addition, given that the structure of the outer membrane (OM) in the cell wall of Gram-negative bacteria is well designed for intrinsic resistance to various antibacterial agents, the high molecular weight of antibiotic hybrids is also detrimental to their activity against Gram-negative microorganisms. Moreover, the hydration sphere, created by hydrophilic carbohydrates, and the reduced fluidity caused by efficient packing of the lipid component restrict the passage of hydrophobic molecules across the OM (Domalaon et al., 2018). What remains is a passage through unspecific, barrel-shaped protein channels called porins. Nevertheless, only small molecules with a molecular weight of ≤600 g/mol are more favorable to pass the molecular sieve imposed by the porins (Vergalli et al., 2020). Fortunately, some antibiotics with a molecular weight of >600 g/mol, such as polymyxins, are able to pass through OM via various uptake mechanisms (e.g., self-promoted entry) (Moubareck, 2020). Agents of this nature are capable of disturbing the electrostatic interactions between the divalent cations such as Mg\(^{2+}\) or Ca\(^{2+}\) and phosphate groups in the lipid, thereby creating a passage through (Deris et al., 2014). Further clarifications of the structural or physicochemical criteria for self-promoted mechanism can extend the antibacterial spectrum of macromolecule-antibiotic hybrids against Gram-negative organisms (Domalaon et al., 2018).

Pioneered by cefiderocol, a cephalosporin siderophore antibiotic approved by the U.S. FDA in November 2019 (Lexicomp, 2021), antibiotic–siderophore conjugates represent an attractive antibiotic hybrid class by conjugating iron-chelating microbial siderophores with an antibiotic to facilitate uptake and antibacterial efficacy (Schalk, 2018; Negash et al., 2019). Specifically, a macrocycle siderophore hybrid, involving the conjugation of a macrocyclic antibiotic with a microbial siderophore or a siderophore mimetic, may overcome the penetration issue to pass through the OM of Gram-negative bacteria. Siderophores benefit bacteria by dissolving and importing iron (Ji et al., 2012). Conjugating with a siderophore can facilitate the entry of the corresponding hybrid through a ferri-siderophore uptake pathway that internalizes iron by an active transport mechanism, that is, a Trojan horse mechanism (Schalk, 2018). Similarly, a self-promoted passage through means of polymyxins can be exploited to force the entry of macrocycle polymyxin conjugates (Negash et al., 2019). Conjugation with polymyxins can not only extend activity against Gram-negative bacteria but also retain activity against resistance mechanism involving overexpression of efflux pumps as well (Negash et al., 2019). Various other hybrid chemical entities have also been reported, including polymyxin B3-tobramycin hybrids with Pseudomonas aeruginosa–selective antibacterial activity and strong potentiation of rifampicin, minocycline, and vancomycin (Domalaon et al., 2017), azithromycin–benzoxaborole hybrid derivatives (Teyyashova et al., 2019), as well as antitubercular rifampicin and clofazimine hybrid (Saravanan et al., 2021). Very recently, design and synthesis of vitamin B12–antibiotic conjugates led to advanced candidates with >500-fold improved activity against Gram-negative bacteria including E. coli, relative to ampicillin, demonstrating that the vitamin B12 conjugate strategy is effective for enabling cellular uptake and antibiotic delivery, thus...
improving antibacterial efficacy (Zhao et al., 2020). Furthermore, among numerous elegant examples by the Schweizer group (Gorityala et al., 2016a; Gorityala et al., 2016b; Yang et al., 2017; Domalaon et al., 2019), the use of antibiotic hybrids as adjuvants such as nebramine-based hybrids (Yang et al., 2019) and lysine-tobramycin conjugates (Lyu et al., 2019) has potentiated the activities of current existing antibiotics including rifampicin and erythromycin, respectively. Similarly, rifamycin–tobramycin conjugate adjuvants were able to break intrinsic resistance of *Pseudomonas aeruginosa* to tetracyclines and chloramphenicol (Idowu et al., 2019).

Some key questions remain to be answered despite the progress and new advances of antibiotic hybrids to clinical development (Domalaon et al., 2018), highlighting the potential to burgeon the antibacterial pipeline. Structure-based drug design, exemplified by X-ray co-crystal studies and molecular modeling, is among techniques capable of ameliorating the way forward of antibiotic hybrids. For example, the co-crystal structure of rifampin with RNA polymerase has highlighted steric-free sites of attachments for conjugates, *vide supra* (Ma and Lynch, 2016; Molodtsov et al., 2017). In addition, TenNor Therapeutics very recently presented the outcome of their phase 2 clinical trial of TNP-2092 and disclosed the co-crystal structure of TNP-2092 bound with bacterial RNA polymerase, along with its interaction with DNA, at the 2020 CBIC, which was held in Suzhou, China, in September 2020 (TenNor, 2020b). Computational strategies were also applied in the design of promising hybrids which are in the early stage of development. For example, in the design of macrocyclic peptide–peptoid hybrids, the crystal structure of the chemokine receptor CXCR4 was used as a template for the homology model of CXCR7 (Boehm et al., 2017). Besides identifying residues important for activity, binding poses from an induced fit docking also spotted spaces in the CXCR7 model that are not occupied by the macropeptide (Boehm et al., 2017). Virtual tools also facilitated the design of VAN–nicin conjugates, by predicting the optimal length of the linker and suitable attachment sites (Arnusch et al., 2008). Nicin is an antimicrobial peptide that binds to lipid II and inhibits the transglycosylation step in the cell wall biosynthesis (Le et al., 2017). Although each has different modes of action, lipid II is targeted by both VAN and nicin. Predicting the optimal spacer and sites of connection was essential to place the constituting elements to their respective binding sites in lipid II (Olsufyeva and Tevyashova, 2017). Computationally guided design of VAN–nicin hybrids led to promising derivatives, with the most active hybrid displaying a 40-fold higher activity than VAN or nicin (Arnusch et al., 2008).

Besides activity profiling, virtual tools depending on prior knowledge or machine learning may enable prediction of specificity, solubility, permeability, and general toxicity of hybrids (Mulligan, 2020; Zin et al., 2020). Prediction of physical properties using molecular dynamics, a computer simulation of the movement of a molecule surrounded by water, may provide a more unbiased model than tools dependent on a database of a large number of compounds with known properties (Mulligan, 2020). Efficient and reliable computational tools for predicting physicochemical properties such as permeability can be essential in the design of macrocyclic hybrids. Macrocycles and their antibiotic hybrids/conjugates are generally considered poor drug-like compounds and often violate desirable parameters for orally bioavailable drug molecules (Lipinski et al., 1997; Zin et al., 2020). Diverse functionalization strategies of macrocycles can modulate physicochemical properties by changing the rigidity, conformation, and basicity of the macrocycle core and/or its side chain (Mallinson and Collins, 2012). In addition, the decrease in degree of freedom by macrocyclization may improve cell permeability of macrocycles (Dougherty et al., 2019). A recent study demonstrated modulation of scaffold rigidity to engineer favorable ADME properties in macroyclic peptides (Furukawa et al., 2020). Finally, drug design strategies, such as N-methylation or replacing NH with sulfur (or vice versa), were found to improve pharmacological activity, solubility, and/or permeability of macrocycles (Mallinson and Collins, 2012; Liras and McClure, 2019; Stadelmann et al., 2020; Buckton et al., 2021). Extending studies of this nature to macrocyclic hybrids is expected to improve their oral bioavailability for systemic uses.

**AUTHOR CONTRIBUTIONS**

ASS and DS designed and prepared the manuscript, and critically reviewed and approved the submission of the final version of the manuscript.

**FUNDING**

This work was supported in part by Leahi Fund to Treat and Prevent Pulmonary Diseases of the Hawai’i Community Foundation (19ADVC-95335).

**REFERENCES**

Adis Insight (2020). Ceflatavacin - Theravance Biopharma. Springer Nature. Available: https://adisinsight.springer.com/drugs/800020586 (Accessed January 11, 2021).

Arnusch, C. J., Bonvin, A. M. J. J., Vered, A. M., Jansen, W. T. M., Liscomb, R. M. J., de Kruijff, B., et al. (2008). The Vancomycin–Nisin(1–12) Hybrid Restores Activity against Vancomycin Resistant Enterococci. *Biochemistry* 47, 12661–12663. doi:10.1021/b801597b

Aslam, B., Wang, W., Arshad, M. I., Khurshid, M., Muzammil, S., Rasool, M. H., et al. (2018). Antibiotic Resistance: a Rundown of a Global Crisis. *Infect. Drug Resist.* 11, 1645–1658. doi:10.2147/IDR.S173867

Aubry-Damon, H., Sossey, C.-J., and Courvalin, P. (1998). Characterization of Mutations in the rpoB Gene That Confer Rifampin Resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 42, 2590–2594. doi:10.1128/AAC.42.10.2590

Beck, A., Goetsch, L., Dumontet, C., and Corvaia, N. (2017). Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates. *Nat. Rev. Drug Discov.* 16, 315–337. doi:10.1038/nrd.2016.268
https://www.who.int/research-observatory/monitoring/processes/antibacterial_products/en/ (Accessed January 11, 2021).

Winstel, V., Xia, G., and Peschel, A. (2014). Pathways and Roles of Wall Teichoic Acid Glycosylation in Staphylococcus aureus. Int. J. Med. Microbiol. 304, 215–221. doi:10.1016/j.ijmm.2013.10.009

Yang, X., Ammeter, D., Idowu, T., Domalaon, R., Brizuela, M., Okunnu, O., et al. (2019). Amphiphilic Nebramine-Based Hybrids Rescue Legacy Antibiotics from Intrinsic Resistance in Multidrug-Resistant Gram-Negative Bacilli. Eur. J. Med. Chem. 175, 187–200. doi:10.1016/j.ejmech.2019.05.003

Yang, X., Goswami, S., Gorityala, B. K., Domalaon, R., Lyu, Y., Kumar, A., et al. (2017). A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. J. Med. Chem. 60, 3913–3932. doi:10.1021/acs.jmedchem.7b00156

Yilmaz, M., Elaldi, N., Balkan, İ. İ., Arslan, F., Batrel, A. A., Bakici, M. Z., et al. (2016). Mortality Predictors of Staphylococcus aureus Bacteremia: a Prospective Multicenter Study. Ann. Clin. Microbiol. Antimicrob. 15, 7. doi:10.1186/s12941-016-0122-8

Yu, X., and Sun, D. (2013). Macroyclic Drugs and Synthetic Methodologies toward Macrocycles. *Molecules* 18, 6230–6268. doi:10.3390/molecules18066230

Yuan, Y., Wang, X., Xu, X., Liu, Y., Li, C., Yang, M., et al. (2020). Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. *ACS Infect. Dis.* 6, 820–831. doi:10.1021/acssinfectdis.9b00374

Yudin, A. K. (2015). Macrocycles: Lessons from the Distant Past, Recent Developments, and Future Directions. *Chem. Sci.* 6, 30–49. doi:10.1039/c4sc03089c

Zhao, S., Wang, Z.-P., Wen, X., Li, S., Wei, G., Gao, J., et al. (2020). Synthesis of Vitamin B12-Antibiotic Conjugates with Greatly Improved Activity against Gram-Negative Bacteria. *Org. Lett.* 22, 6632–6636. doi:10.1021/acs.orglett.0c02403

Zhou, C., Lehar, S., Gutierrez, J., Rosenberger, C. M., Ljumanovic, N., Dinoso, J., et al. (2016). Pharmacokinetics and Pharmacodynamics of DSTA4637A: A Novel THIOMAB Antibody Antibiotic Conjugate against Staphylococcus aureus in Mice. *mAbs* 8, 1612–1619. doi:10.1080/19420862.2016.1229722

Zhou, Q. (2017). Site-specific Antibody Conjugation for ADC and beyond. *Biomedicines* 5, 64. doi:10.3390/biomedicines5040064

Zimmerli, W., and Sendi, P. (2019). Role of Rifampin against Staphylococcal Biofilm Infections *In Vitro*, in Animal Models, and in Orthopedic-Device-Related Infections. *Antimicrob. Agents Chemother.* 63, e01746–18. doi:10.1128/AAC.01746-18

Zin, P. P. K., Williams, G. J., and Ekins, S. (2020). Cheminformatics Analysis and Modeling with macrolactoneDB. *Sci. Rep.* 10, 6284. doi:10.1038/s41598-020-63192-4

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Surur and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.